Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
The British Journal of Dermatology|September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studiesA B Kimball, K A Papp, K Reich, et al.The British Journal of Dermatology|February 7, 2018
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)R G Langley, K Papp, M Gooderham, et al.The British Journal of Dermatology|September 24, 2019
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12K Papp, C Maari, A Cauthen, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 9, 2017
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE studyK Reich, M Gooderham, A Bewley, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2019
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trialsA Blauvelt, H Sofen, K Papp, et al.The British Journal of Dermatology|July 30, 2017
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasisK Papp, H Bachelez, A Costanzo, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 22, 2016
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)K Reich, M Gooderham, L Green, et al.The British Journal of Dermatology|July 17, 2016
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trialR Bissonnette, K A Papp, Y Poulin, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 17, 2022
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasisM Gooderham, A Pinter, L K Ferris, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2019
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28K A Papp, K Reich, A Blauvelt, et al.Pageof 3